Renaissance Acquisition Holdings, LLC, a RoundTable Healthcare Partners portfolio company, and GlaxoSmithKline announced today that they have entered into an agreement giving Renaissance the rights in the USA to manufacture, market and sell six dermatology and three anti-viral products from GSK.

The products from GSK and Stiefel, a GSK company, which will be marketed through Renaissance’s branded division Prestium Pharma, include:

Evoclin® (clindamycin phosphate) Foam,1% Extina® (ketoconazole) Foam,2% Luxiq® (betamethasone valerate) Foam, 0.12% Olux® (clobetasol propionate) Foam, 0.05% Olux-E® (clobetasol propionate) Foam, 0.05% Vusion® (miconazole nitrate 0.25%, zinc oxide 15% and white petrolatum 81.35%) Ointment Zovirax® (acyclovir) Capsules Zovirax® (acyclovir) Tablets Zovirax® (acyclovir) Suspension

Pierre Fréchette, President and CEO of Renaissance, stated, “This transaction represents a significant milestone for Renaissance, and is in-line with our strategy of acquiring niche products that we can both manufacture within our internal network and market through our strong commercial group. The RoundTable team was instrumental in helping to source, diligence and complete such an important acquisition.”

Simon Jose, Stiefel President, said, “This agreement allows US patients to continue to have access to treatments they value and allows the Stiefel US Team to focus on growth and development of new treatments within our core dermatology portfolio.”

John Denman, General Manager of Prestium, commented, “We are excited to add these mature specialty brands to Prestium’s growing portfolio, and look forward to continuing to supply such important products to our customers and to patients across the country.”